Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: A randomised double-blind placebo-controlled study

Diabetologia

Volumn 55, Issue 4, 2012, Pages 915-925

  Eliasson, B ^a   Moller Goede D ^b   Eeg Olofsson, K ^a   Wilson, C ^c   Cederholm, J ^d   Fleck, P ^c   Diamant, M ^b   Taskinen, M R ^e   Smith, U ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TAKEDA PHARMACEUTICALS   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Alogliptin; DPP 4 inhibitor; Incretins; Postprandial lipids; Postprandial lipoproteins; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; APOLIPOPROTEIN B48; CHYLOMICRON; HEMOGLOBIN A1C; LIPID; LIPOPROTEIN; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOMETABOLIC RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LIPID DIET; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STOMACH ULCER;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MIDDLE AGED; PIPERIDINES; POSTPRANDIAL PERIOD; THIAZOLIDINEDIONES; TREATMENT OUTCOME; URACIL;

EID: 84859463659     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2447-3     Document Type: Article

References (33)

1. Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733-749
2. Chapman MJ, Ginsberg HN, Amarenco P et al (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 11:1345-1361
3. Bandsma RH, Lewis GF (2010) Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia. Atherosclerosis 212:40-41
4. Hsieh J, Longuet C, Baker CL et al (2010) The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53:552-561
5. Bunck MC, Corner A, Eliasson B et al (2010) One-year treatment with exenatide vs. insulin glargine: effects on postprandial glyce-mia, lipid profiles, and oxidative stress. Atherosclerosis 212:223-229
6. Matikainen N, Manttari S, Schweizer A et al (2006) Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:2049-2057
7. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P (2011) Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metabol 13:366-373
8. Lenhard JM, Croom DK, Minnick DT (2004) Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 324:92-97
9. Al Majali K, Cooper MB, Staels B, Luc G, Taskinen MR, Betteridge DJ (2006) The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipopro-tein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 49:527-537
10. Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA (2007) Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 50:1723-1731
11. Goldberg RB, Kendall DM, Deeg MA et al (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547-1554
12. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE (2001) The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 12:413-423
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
14. Mero N, Syvanne M, Eliasson B, Smith U, Taskinen MR (1997) Postprandial elevation of apoB-48-containing triglyceride-rich particles and retinyl esters in normolipemic males who smoke. Arte-rioscler Thromb Vasc Biol 17:2096-2102
15. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesteroi in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
16. Karpe F, Hamsten A (1994) Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 35:1311-1317
17. Kinoshita M, Kojima M, Matsushima T, Teramoto T (2005) Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 351:115-120
18. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD (2010) Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 212:217-222
19. Ban K, Hui S, Drucker DJ, Husain M (2009) Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 3:245-259
20. Nakajima K, Nakano T, Moon HD et al (2009) The correlation between TG vs remnant lipoproteins in the fasting and postprandial plasma of 23 volunteers. Clin Chim Acta 404:124-127
21. Dallinga-Thie GM, Franssen R, Mooij HL et al (2010) The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 211:1-8
22. Williams KJ, Chen K (2010) Recent insights into factors affecting remnant lipoprotein uptake. Curr Opin Lipidol 21:218-228
23. Adiels M, Olofsson SO, Taskinen MR, Boren J (2008) Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:1225-1236
24. Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679-689
25. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G (1995) Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158-166
26. Duez H, Lamarche B, Valero R et al (2008) Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 117:2369-2376
27. Adeli K, Lewis GF (2008) Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol 19:221-228
28. Pavlic M, Xiao C, Szeto L, Patterson BW, Lewis GF (2010) Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes 59:580-587
29. Gupta NA, Mells J, Dunham RM et al (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51:1584-1592
30. Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, Pijl H (2010) GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 299:E318-324
31. Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic stea-tohepatitis. N Engl J Med 355:2297-2307
32. Adiels M, Taskinen MR, Packard C et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755-765
33. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H (2009) Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pio-glitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 157:415-426